G Kennedy1, V Spence, C Underwood, J J F Belch. 1. Vascular Diseases Research Unit, University Department of Medicine, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK. g.kirk@dundee.ac.uk
Abstract
BACKGROUND/AIMS: Many patients with chronic fatigue syndrome (CFS) have symptoms that are consistent with an underlying viral or toxic illness. Because increased neutrophil apoptosis occurs in patients with infection, this study examined whether this phenomenon also occurs in patients with CFS. METHODS: Apoptosis was assessed in patients with CFS in conjunction with concentrations of the anti-inflammatory cytokine, transforming growth factor beta1 (TGFbeta1). RESULTS: The 47 patients with CFS had higher numbers of apoptotic neutrophils, lower numbers of viable neutrophils, increased annexin V binding, and increased expression of the death receptor, tumour necrosis factor receptor-I, on their neutrophils than did the 34 healthy controls. Patients with CFS also had raised concentrations of active TGFbeta1 (p < 0.005). CONCLUSIONS: These findings provide new evidence that patients with CFS have an underlying detectable abnormality in their immune cells.
BACKGROUND/AIMS: Many patients with chronic fatigue syndrome (CFS) have symptoms that are consistent with an underlying viral or toxic illness. Because increased neutrophil apoptosis occurs in patients with infection, this study examined whether this phenomenon also occurs in patients with CFS. METHODS: Apoptosis was assessed in patients with CFS in conjunction with concentrations of the anti-inflammatory cytokine, transforming growth factor beta1 (TGFbeta1). RESULTS: The 47 patients with CFS had higher numbers of apoptotic neutrophils, lower numbers of viable neutrophils, increased annexin V binding, and increased expression of the death receptor, tumour necrosis factor receptor-I, on their neutrophils than did the 34 healthy controls. Patients with CFS also had raised concentrations of active TGFbeta1 (p < 0.005). CONCLUSIONS: These findings provide new evidence that patients with CFS have an underlying detectable abnormality in their immune cells.
Authors: I E Nwakoby; K Reddy; P Patel; N Shah; S Sharma; M Bhaskaran; N Gibbons; A A Kapasi; P C Singhal Journal: Infect Immun Date: 2001-05 Impact factor: 3.441
Authors: Jose G Montoya; Holden T Maecker; Yael Rosenberg-Hasson; Mark M Davis Journal: Proc Natl Acad Sci U S A Date: 2017-10-30 Impact factor: 11.205
Authors: John W Gow; Suzanne Hagan; Pawel Herzyk; Celia Cannon; Peter O Behan; Abhijit Chaudhuri Journal: BMC Med Genomics Date: 2009-06-25 Impact factor: 3.063
Authors: Karin Olson; A Robert Turner; Kerry S Courneya; Catherine Field; Godfrey Man; Marilyn Cree; John Hanson Journal: Support Care Cancer Date: 2007-07-24 Impact factor: 3.603
Authors: Suzanne D Vernon; Toni Whistler; Barbara Cameron; Ian B Hickie; William C Reeves; Andrew Lloyd Journal: BMC Infect Dis Date: 2006-01-31 Impact factor: 3.090
Authors: Ekua W Brenu; Donald R Staines; Oguz K Baskurt; Kevin J Ashton; Sandra B Ramos; Rhys M Christy; Sonya M Marshall-Gradisnik Journal: J Transl Med Date: 2010-01-11 Impact factor: 5.531
Authors: Angela P Presson; Eric M Sobel; Jeanette C Papp; Charlyn J Suarez; Toni Whistler; Mangalathu S Rajeevan; Suzanne D Vernon; Steve Horvath Journal: BMC Syst Biol Date: 2008-11-06